3 results
Approved WMORecruitment stopped
Improvement of the functional recovery of patients with a hipfracture and the prevention of re-surgery.
Approved WMORecruitment stopped
1. To assess the effect of odanacatib 50 mg once weekly versus placebo on lumbar spine BMD over 24 months.2. To assess the safety and tolerability of odanacatib 50 mg once weekly compared to placebo.
Approved WMOWill not start
To analyze the difference in fT>MIC at the target site and infection rate for a single dose of 1 and 2g of cefazolin.